User:Kevin Gorman/hyq

Kevin Gorman/hyq
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Routes of; administration	Subcutaneous

Sources

Yeah, I really do just list my sources first while developing an article

Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI) ^[1]
Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers - it involves minipigs! ^[2]
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency^[3]
Pharmaceutical Approval Update ^[4]
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration (antibody info) ^[5]
Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders (this one requires EBSCO) ^[6]

^ Wasserman, Richard L.; Stein, Mark R.; Melamed, Isaac; Kobrynski, Lisa J.; Gupta, Sudhir; Puck, Jennifer M.; Rubinstein, Arye; Engl, Werner; McCoy, Barbara; Leibl, Heinz; Yel, Leman (February 2015). "Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)". Journal of Allergy and Clinical Immunology. 135 (2): AB96. doi:10.1016/j.jaci.2014.12.1247. {{cite journal}}: |access-date= requires |url= (help)
^ Dychter, Samuel S.; Harrigan, Rena; Bahn, Jesse D.; Printz, Marie A.; Sugarman, Barry J.; DeNoia, Emanuel; Haughey, David B.; Fellows, Daniel; Maneval, Daniel C. (February 2014). "Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers". Clinical Therapeutics. 36 (2): 211–224. doi:10.1016/j.clinthera.2013.12.013.
^ Wasserman, Richard L.; Melamed, Isaac; Stein, Mark R.; Gupta, Sudhir; Puck, Jennifer; Engl, Werner; Leibl, Heinz; McCoy, Barbara; Empson, Victoria G.; Gelmont, David; Schiff, Richard I. (October 2012). "Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency". Journal of Allergy and Clinical Immunology. 130 (4): 951–957.e11. doi:10.1016/j.jaci.2012.06.021. {{cite journal}}: |access-date= requires |url= (help)
^ Gohil K (2014). "Pharmaceutical approval update". P T. 39 (11): 746–72. PMC 4218669. PMID 25395816.
^ Rosengren, Sanna; Dychter, Samuel S.; Printz, Marie A.; Huang, Lei; Schiff, Richard I.; Schwarz, Hans-Peter; McVey, John K.; Drake, Fred H.; Maneval, Dan C.; Kennard, Don A.; Frost, Gregory I.; Sugarman, Barry J.; Muchmore, Douglas B. (13 May 2015). "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration". The AAPS Journal. 17 (5): 1144–1156. doi:10.1208/s12248-015-9782-0. {{cite journal}}: |access-date= requires |url= (help)
^ Sanford, Mark (13 June 2014). "Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders". BioDrugs. 28 (4): 411–420. doi:10.1007/s40259-014-0104-3. {{cite journal}}: |access-date= requires |url= (help); no-break space character in |title= at position 24 (help)

Medical use

Inflammation

Other uses

Dosage

Adverse effects

Contraindications

Skin

Other adverse effects

Interactions

Chemical properties

Mechanism of action

Additional mechanisms

Pharmacokinetics

History

References

<references/

[a&ci-1] Wasserman, Richard L.; Stein, Mark R.; Melamed, Isaac; Kobrynski, Lisa J.; Gupta, Sudhir; Puck, Jennifer M.; Rubinstein, Arye; Engl, Werner; McCoy, Barbara; Leibl, Heinz; Yel, Leman (February 2015). "Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)". Journal of Allergy and Clinical Immunology. 135 (2): AB96. doi:10.1016/j.jaci.2014.12.1247. {{cite journal}}: |access-date= requires |url= (help)

[minipigs-2] Dychter, Samuel S.; Harrigan, Rena; Bahn, Jesse D.; Printz, Marie A.; Sugarman, Barry J.; DeNoia, Emanuel; Haughey, David B.; Fellows, Daniel; Maneval, Daniel C. (February 2014). "Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers". Clinical Therapeutics. 36 (2): 211–224. doi:10.1016/j.clinthera.2013.12.013.

[jacipi-3] Wasserman, Richard L.; Melamed, Isaac; Stein, Mark R.; Gupta, Sudhir; Puck, Jennifer; Engl, Werner; Leibl, Heinz; McCoy, Barbara; Empson, Victoria G.; Gelmont, David; Schiff, Richard I. (October 2012). "Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency". Journal of Allergy and Clinical Immunology. 130 (4): 951–957.e11. doi:10.1016/j.jaci.2012.06.021. {{cite journal}}: |access-date= requires |url= (help)

[pap-4] Gohil K (2014). "Pharmaceutical approval update". P T. 39 (11): 746–72. PMC 4218669. PMID 25395816.

[antibodies-5] Rosengren, Sanna; Dychter, Samuel S.; Printz, Marie A.; Huang, Lei; Schiff, Richard I.; Schwarz, Hans-Peter; McVey, John K.; Drake, Fred H.; Maneval, Dan C.; Kennard, Don A.; Frost, Gregory I.; Sugarman, Barry J.; Muchmore, Douglas B. (13 May 2015). "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration". The AAPS Journal. 17 (5): 1144–1156. doi:10.1208/s12248-015-9782-0. {{cite journal}}: |access-date= requires |url= (help)

[adis-6] Sanford, Mark (13 June 2014). "Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders". BioDrugs. 28 (4): 411–420. doi:10.1007/s40259-014-0104-3. {{cite journal}}: |access-date= requires |url= (help); no-break space character in |title= at position 24 (help)

[1]

[2]

[3]

[4]

[5]

[6]